In view of the high frequency of gouty arthritis reported in Filipinos, a population of normal Filipino males and an age‐matched group of Caucasian males were examined. The mean serum uric acid value (with standard deviation) was found to be 6.3 ± 1.4 mg. per 100 ml. for Filipinos and 5.0 ± 1.1 mg. per 100 ml. for Caucasians, using the uricaseultraviolet spectrophotometric method of Praetorius. The serum uric acid frequency distribution curve was found to be symmetrical for the Caucasians and skewed to high values for the Filipinos.
Background-The disparities in stroke care between specialized stroke units and non-stroke units have been reported. While most of the existing studies investigated how intrinsic characteristics of specific treatment units have impact on the outcomes, the influence of patients' characteristics on functional outcomes of recombinant tissue plasminogen activator-treated patients in specialized stroke units and non-stroke units is not fully understood. Method-The demographic and clinical risk factors that significantly impact functional improvement outcomes in recombinant tissue plasminogen activator-treated acute ischemic stroke in the non-stroke unit and the specialized stroke unit were determined. Univariate analysis was used to determine improved functional differences, while adjusted multivariable models were used to determine the association between demographic and clinical variables on the functional outcome. Results-In stroke patients that received recombinant tissue plasminogen activator in the specialized stroke unit and the non-stroke unit, a history of previous transient ischemic attack (ORadj, 0.347, 95% CI (0.160, 0.752); p=0.007) and patients taking antiplatelet medications (ORadj, 1.954, 95% CI (1.116, 3.421, p=0.019) were significantly associated with improved functional outcome. Patients with a history of carotid artery stenosis (ORadj, 5.265, 95% CI (1.067, 2.977), p=0.041) and a history of transient ischemic attack (ORadj, 0.295, 95% CI (0.100, 0.872), p=0.027) were significantly associated with improved functional outcome following treatment with recombinant tissue plasminogen activator in the specialized stroke unit. In the adjusted model analysis for the non-stroke unit, the major predictors of functional outcome were: the NIH stroke scale (ORadj=1.381, 95% CI (1.086, 1.757), p=0.009), the risk of mortality (ORadj =0.691, 95% CI (0.518, 0.922) p=0.012), female gender (ORadj=0.306, 95% CI (0.120, 0.778), p=0.013), and race/ethnicity (ORadj=0.285, 95% CI (0.084, 0.970), p=0.045). Conclusion-After the adjusted analysis, the specialized stroke unit and non-stroke unit reveal significantly improved functional outcomes for patients treated with recombinant tissue plasminogen activator in few clinical variables. Values for functional outcomes were not significantly associated with most of the variables for treated patients in both the specialized stroke unit and non-stroke unit even after adjustment in the recombinant tissue plasminogen activator-treated stroke population.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.